Michael is a specialist patent attorney in the in the pharmaceutical field and has more than 20 years of experience at all stages of a product, from early phase discovery to defending marketed pharmaceutical products. Michael acts for a wide range of clients including multinationals, SMEs, universities and research organisations.
Prior to joining HGF Michael worked "in-house" as a patent attorney for 13 years for AstraZeneca and use this experience and insight to advise clients and develop IP strategies that are focused on their commercial objectives.
His work covers patent drafting, global prosecution, patent term extensions and SPCs, freedom to operate analysis and opinions, regulatory exclusivity as well as significant experience in IP due diligence evaluation. Michael also handles EPO oppositions and appeals for his clients.
Physics (First Class Honours)
The European Patent Office today confirmed in Decision G4/19 of the Enlarged board of Appeal that a European patent application can be refused for ‘double patenting’. Such a refusal can …Read article
Managing Intellectual Property IP Stars 2021, comprising the highly recommended IP professionals, has now been published. HGF is delighted to have 14 European attorneys listed. IP STARS is the leading …Read article
Pharmaceutical and biotechnology patent applications also make top 10 most patented. Recent statistics published by the EPO show that a total of 14,295 European patent applications were filed in 2020 …Read article
The 2021 EPO Guidelines provide much needed guidance on how to protect antibodies in Europe. Biological drugs including therapeutic antibodies have become increasingly important to the pharmaceutical industry. The European …Read article
Opportunities for additional pharmaceutical product patent protection in Europe, based on the use of a drug to treat a patient exhibiting a biomarker indicative of drug response. Recent years have …Read article
Exploring the growth of patents for connected medical devices, and how best to protect them. The Internet of Things (IoT) is expected to change our lives by creating a connected …Read article
To waive, or not to waive, that is the question. The earliest identified date of a patient presenting with symptoms of a “novel coronavirus” in Wuhan, China is reported to …Read article
If you would like to discuss how HGF could help you, contact one of our IP specialists.